Unleash the potential of genomic medicine using AI
We optimize the use of biological data-guided rational design and AI to predict the best molecular constructs in pre-clinical genomic medicine.
ALFRED AI
Our Proprietary AI-Led Framework for Rational Exploration in Drug design
Combining advanced algorithms, curated databases, and cutting-edge computational biology, we optimize therapeutic candidates for safety and efficacy across diverse modalities such as AAV, lentivirus, and nanoparticles.
Applications
That Target Product Profile Moment
Our AI-driven approach empowers collaborators to achieve breakthrough solutions in genomic medicine, saving time and resources while delivering precise, effective cell & gene modalities across therapeutic areas.
Gene & RNA-based therapies
Target Receptors Identification & Viral Vector Design
- Tech R&D
- In Silico Design
- Wet Lab Validation
- CNSCNS: 77%
- OphthalmologyOphthalmology: 56%
- Rare diseaseRare disease: 56%
- OncologyOncology: 56%
Non Viral Vector Design
- Tech R&D
- In Silico Design
- Wet Lab Validation
- OncologyOncology: 77%
Payload design
- Tech R&D
- In Silico Design
- Wet Lab Validation
- OncologyOncology: 56%
Bioproduction
Bioproduction optimization
- Tech R&D
- In Silico Design
- Wet Lab Validation
- 2 programs (AAV, LV)2 programs (AAV, LV): 80%
Cell Therapy
Cell Therapy Pipeline
- Tech R&D
- In Silico Design
- Wet Lab Validation
- CAR designCAR design: 40%
- Viral vectorsViral vectors: 40%
About Us
Mission & Team
WhiteLab Genomics stands at the convergence of AI and biology. Founded in 2019, backed by Y-Combinator, we’re pioneering the accelerated development of life-saving genomic medicines. By leveraging our proprietary technology, we use AI and advanced computational methods to analyze complex biological data to significantly accelerate and de-risk drug development.
Careers
Join the WhiteLab Team!
Be part of a team where care is at our heart, collective potential is embraced, and proactive communication, respect, and a can-do attitude form the foundation of our achievements. Together, we strive to make groundbreaking advancements in medicine and transform the future of healthcare.
Media Center
Partners
"As a company specialized in drug development, we know the hardships of the field and therefore we recognize the added value of AI powered platforms like the WhiteLab Genomics’ platform applied to the early stages of drugs R&D. We look forward to fully exploiting the potential of AI based solutions to develop drugs, de-risk assets,any toxicity, and ensure that we bring the most personalized drugs to patients."
“We are encouraged by the investment in WIDGeT. As genomic medicine matures, there is an ever-increasing need for optimization of the delivery vehicles for these nucleic acid medicines. Working with WhiteLab Genomics, the TarGeT Lab at Nantes University and Institut Imagine, we aim to create novel adeno-associated viral vectors with tropisms to currently hard-to-reach cells.”
“This partnership with WhiteLab Genomics will accelerate our mission to develop universal immuno-gene therapies for cancer. Their expertise in AI applications for genomic medicine make them an ideal match to leverage the timely advancements in AI to accelerate our indication discovery efforts. We believe we are taking a completely novel approach to identifying new indications for AAV gene therapies.”
“Institut Imagine is proud to participate in this large-scale project aiming to integrate AI into the development and optimization of gene therapies. Our expertise in the field of podocytopathies and the use of innovative technological devices will enhance the effectiveness of gene therapies, harnessing the remarkable development of AI in biology and healthcare. These projects once again demonstrate the importance of public-private, multidisciplinary, and multi-partner collaborations.”
“ I am very honored to contribute to this synergy of experts to improve gene therapy engineering. With the GEAR project, we will be able to have a significant impact on the field of retinal health and visual health. ”
“The tools developed by WhiteLab will make it possible for us to review thousands of sequences and devise new and innovative combinations. We aim to develop a new generation of more specific AAV vectors, contributing to the emergence of original treatments for neuromuscular disorders.”
“This collaboration with WhiteLab Genomics will allow us to integrate a large body of information on critical parameters and their interconnections in complex processes so that we can very rapidly adapt our experiments; a new way for us to work, to accelerate our strategic projects and to innovate.”
References & Awards
